Enzychem Lifesciences Corporation, a pharmaceutical company, focuses on the development of oral small molecule therapies for patients with unmet medical needs for oncology, metabolic diseases, and inflammatory diseases in South Korea. It is also developing potential therapies based on EC-18 technology platform to treat chemotherapy-induced neutropenia, chemoradiation therapy-induced oral mucositis, and acute radiation syndrome. The company was founded in 1999 and is headquartered in Seoul, South Korea.